Vincent A. Miller
#107,106
Most Influential Person Now
Vincent A. Miller's AcademicInfluence.com Rankings
Vincent A. Millerphilosophy Degrees
Philosophy
#4382
World Rank
#6873
Historical Rank
Logic
#1848
World Rank
#2702
Historical Rank
Vincent A. Millerbiology Degrees
Biology
#5701
World Rank
#8243
Historical Rank
Computational Biology
#91
World Rank
#91
Historical Rank
Molecular Biology
#534
World Rank
#547
Historical Rank
Download Badge
Philosophy Biology
Vincent A. Miller's Degrees
- PhD Molecular Biology University of California, San Francisco
- Bachelors Biochemistry University of California, Berkeley
Why Is Vincent A. Miller Influential?
(Suggest an Edit or Addition)Vincent A. Miller's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005) (3427)
- EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. (2004) (3411)
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017) (2129)
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers (2013) (2004)
- Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. (2004) (1790)
- Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (2004) (1779)
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing (2013) (1663)
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing (2012) (1620)
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (2007) (1619)
- TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. (2005) (1538)
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers (2017) (1504)
- Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. (2005) (1488)
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens (2000) (1254)
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (2005) (1226)
- Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer (2012) (1043)
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. (2012) (927)
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. (2018) (816)
- Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. (2000) (812)
- Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (2006) (807)
- ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. (2002) (773)
- Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. (2004) (750)
- Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. (2010) (734)
- Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (2006) (709)
- Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011) (635)
- Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. (2005) (610)
- Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. (2015) (601)
- HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. (2012) (598)
- Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. (2015) (573)
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation (2010) (570)
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay (2011) (547)
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma (2008) (534)
- Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer (2013) (506)
- Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer (2014) (490)
- Kinase fusions are frequent in Spitz tumours and spitzoid melanomas (2014) (465)
- Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. (2013) (452)
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 (2012) (421)
- Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. (2010) (402)
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR (2011) (397)
- Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. (2014) (395)
- Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer (2006) (393)
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. (2012) (389)
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design (2011) (386)
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials (2009) (386)
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors (2015) (385)
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade (2016) (370)
- New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. (2014) (363)
- Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. (2014) (360)
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. (2015) (360)
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) (333)
- New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer (2011) (333)
- D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. (2013) (318)
- "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. (2011) (317)
- Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. (2016) (309)
- Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. (2014) (304)
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database (2019) (300)
- Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. (2008) (300)
- Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus (2007) (297)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (294)
- Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (2013) (285)
- Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma (2008) (263)
- Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. (2011) (255)
- Biliary cancer: Utility of next‐generation sequencing for clinical management (2016) (254)
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations (2016) (252)
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms (2014) (229)
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. (2019) (228)
- Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches (2015) (225)
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer (2010) (223)
- Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. (2006) (217)
- High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer (2010) (212)
- The distribution of BRAF gene fusions in solid tumors and response to targeted therapy (2015) (209)
- Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. (2016) (209)
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. (2018) (206)
- Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 (2015) (199)
- Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors (2013) (195)
- A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). (2009) (195)
- Practical management of patients with non-small-cell lung cancer treated with gefitinib. (2005) (193)
- Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. (2015) (192)
- Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. (1997) (190)
- EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. (2008) (185)
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors (2018) (184)
- Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. (2016) (182)
- Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. (2018) (173)
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. (2019) (165)
- Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. (2016) (164)
- Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. (2019) (164)
- ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. (2013) (164)
- A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal (2018) (164)
- Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. (2011) (159)
- Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures (2017) (159)
- Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. (2013) (155)
- Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. (2014) (154)
- Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. (2002) (152)
- BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition (2013) (149)
- Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. (2015) (142)
- Genomic Profiling of Small-Bowel Adenocarcinoma (2017) (136)
- Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA (2018) (136)
- Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy (2014) (133)
- Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. (2012) (132)
- Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. (2016) (132)
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma (2011) (131)
- Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib (2011) (129)
- A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations (2011) (126)
- Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 (2018) (123)
- Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. (2014) (123)
- Inactivation of Capicua drives cancer metastasis (2016) (122)
- The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. (2016) (121)
- Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. (2015) (120)
- Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin (2004) (119)
- Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. (2017) (119)
- Phase II trial of a 75‐mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non‐small cell lung cancer (1995) (116)
- Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). (2010) (116)
- A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma (2013) (116)
- Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) (116)
- Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or N-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin (2004) (115)
- Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. (2008) (113)
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. (2019) (112)
- Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations (2013) (111)
- Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms (2013) (109)
- Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping (2012) (108)
- Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling (2017) (107)
- Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. (2016) (106)
- A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples (2019) (105)
- The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
- Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer (2014) (102)
- Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy (2016) (101)
- Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer (2007) (101)
- Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping (2017) (100)
- Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer (2007) (100)
- A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. (2002) (100)
- Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. (2016) (99)
- HER 2 Amplifi cation : A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR T 790 M Mutation (2012) (99)
- Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence (2016) (98)
- Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome (2016) (97)
- Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. (2013) (97)
- Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. (2019) (96)
- Phase I study of green tea extract in patients with advanced lung cancer (2004) (94)
- Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors (2018) (93)
- EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. (2015) (92)
- Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations (2016) (91)
- The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy (2019) (91)
- Inhibiting MEK in MAPK pathway-activated myeloma (2015) (90)
- Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. (1999) (89)
- EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. (2016) (89)
- Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer (2014) (89)
- Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer (2010) (88)
- Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target (2016) (88)
- Identification of NTRK fusions in pediatric mesenchymal tumors (2017) (88)
- Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. (2016) (87)
- Identification and characterization of RET fusions in advanced colorectal cancer (2015) (87)
- Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report (2010) (86)
- Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. (2014) (85)
- A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung (2010) (84)
- Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. (2015) (83)
- Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. (2015) (83)
- ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer (2017) (83)
- Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma (2014) (82)
- Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. (2015) (81)
- Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. (2016) (81)
- Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib (2011) (81)
- High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. (2017) (80)
- Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. (2018) (78)
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations (2016) (78)
- HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib (2017) (78)
- Pulmonary toxicity associated with erlotinib. (2007) (78)
- Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors (2019) (78)
- Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (2017) (77)
- RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. (2015) (77)
- Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. (2016) (75)
- I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. (2015) (74)
- Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma (2005) (73)
- Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1) (2013) (72)
- Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. (2016) (72)
- An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. (2017) (71)
- Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. (2017) (71)
- The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. (2003) (71)
- STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion (2015) (70)
- Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. (2015) (69)
- Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. (2016) (69)
- Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients (2006) (68)
- TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics (2016) (67)
- Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. (2010) (67)
- Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. (2016) (67)
- Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. (2015) (66)
- Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. (2003) (66)
- Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity (2020) (66)
- A phase I trial of perillyl alcohol in patients with advanced solid tumors (2003) (66)
- On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation (2019) (65)
- Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. (2017) (65)
- Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies (2016) (65)
- Evaluation of 122 advanced‐stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies (2016) (65)
- 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). (2004) (64)
- Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. (2015) (64)
- Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. (2019) (64)
- Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study. (2018) (64)
- Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. (2014) (63)
- Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms (2014) (63)
- Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas (2017) (63)
- Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. (2000) (63)
- Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. (2000) (63)
- BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. (2016) (63)
- Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. (2005) (62)
- Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations (2015) (62)
- Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers (2016) (61)
- Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein (2014) (60)
- Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. (2015) (60)
- Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer (2007) (60)
- A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). (2009) (59)
- Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib (2011) (59)
- A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors (2007) (58)
- A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). (2010) (58)
- Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. (2004) (57)
- Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies (2014) (57)
- Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. (2017) (57)
- Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene (2011) (56)
- ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS (2012) (55)
- Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. (2016) (55)
- Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. (2009) (55)
- Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas (2012) (55)
- Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer (2021) (54)
- Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer (2018) (54)
- A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. (2014) (54)
- Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. (2000) (54)
- Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies (2014) (53)
- Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias (2016) (52)
- Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden (2017) (52)
- 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. (2003) (51)
- Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. (1997) (51)
- ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. (2016) (51)
- XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib (2012) (51)
- Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer (2019) (50)
- Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer (2016) (49)
- A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors (2010) (49)
- Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. (1995) (48)
- Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. (2015) (48)
- Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling (2019) (48)
- Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker (2017) (48)
- Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. (2009) (47)
- Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets (2015) (47)
- Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. (2014) (47)
- EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. (2006) (46)
- Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. (2018) (46)
- Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia (2018) (45)
- Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation (2011) (45)
- Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. (2014) (44)
- Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus (2018) (43)
- Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies (2017) (43)
- Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. (2015) (43)
- Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA) (2007) (43)
- Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy (2017) (41)
- Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration. (2017) (41)
- Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). (2019) (40)
- Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. (2020) (40)
- Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer (2019) (40)
- Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer (2012) (39)
- New chemotherapeutic agents for non-small cell lung cancer. (1995) (39)
- Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. (2020) (38)
- Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. (2015) (38)
- Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy (2019) (38)
- Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial (2008) (38)
- Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. (2020) (38)
- Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma (2016) (38)
- Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. (2017) (38)
- Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. (2016) (37)
- Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial (2008) (37)
- Comprehensive genomic profiling of malignant phyllodes tumors of the breast (2017) (37)
- Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. (2003) (36)
- Modulation of all-trans retinoic acid pharmacokinetics by liarozole (2004) (35)
- Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. (2020) (35)
- Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors (2016) (35)
- Genomic Landscape of Appendiceal Neoplasms. (2018) (35)
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma (2018) (33)
- Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? (2004) (33)
- A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. (2016) (33)
- A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases (2017) (33)
- Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening (2015) (32)
- Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities (2018) (32)
- Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. (2017) (32)
- Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. (2000) (32)
- Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer (2017) (32)
- Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2 (2008) (32)
- Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. (2017) (31)
- Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials (2018) (31)
- Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma. (2017) (31)
- Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. (2019) (31)
- Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing (2016) (31)
- Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer. (2016) (31)
- Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma. (1995) (31)
- Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. (2015) (30)
- A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors (2007) (30)
- Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors (2018) (30)
- BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. (2017) (30)
- Significant and durable clinical benefit from trastuzumab in 2 patients with HER2‐amplified salivary gland cancer and a review of the literature (2017) (30)
- Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. (2016) (30)
- Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. (2019) (30)
- Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. (2016) (30)
- Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. (2016) (30)
- Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. (2020) (30)
- Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. (2017) (29)
- The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. (2015) (29)
- Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. (2016) (29)
- Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial (2007) (28)
- BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. (2018) (28)
- Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion (2016) (27)
- Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. (2019) (27)
- Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. (2000) (27)
- BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy (2018) (26)
- Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study (2017) (26)
- Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary (2014) (26)
- Comprehensive genetic alteration profiling in primary and recurrent glioblastoma (2018) (26)
- Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC) (2005) (26)
- Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. (2018) (26)
- Gemcitabine-Induced Peripheral Edema: Report on 15 Cases and Review of the Literature (2003) (26)
- Trastuzumab in the treatment of non-small cell lung cancer. (2002) (26)
- RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients (2017) (25)
- Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. (2016) (25)
- Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery (2000) (25)
- A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion (2011) (25)
- Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. (1998) (25)
- Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center (2017) (24)
- Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden (2018) (24)
- EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial (2005) (24)
- Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness (2019) (24)
- Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors (2018) (24)
- Kinase domain activation through gene rearrangement in multiple myeloma (2018) (23)
- Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. (2010) (23)
- A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). (2013) (23)
- Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies (2018) (22)
- Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib. (2016) (22)
- Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer. (1999) (22)
- Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA (2020) (22)
- Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay (2018) (22)
- Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. (2015) (22)
- Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma. (2016) (22)
- Approach to evaluating tumor mutational burden in routine clinical practice. (2018) (22)
- Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study (2016) (21)
- A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). (2009) (21)
- Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation. (2015) (21)
- AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations (2022) (21)
- SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma. (2004) (21)
- Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer. (2005) (20)
- Pilot trial of ZD1839 (IressaTM), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC) (2000) (20)
- Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. (2014) (20)
- Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings (2018) (20)
- Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. (2014) (20)
- MA14.01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC) (2017) (20)
- EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. (2008) (19)
- NTRK1 gene fusions as a novel oncogene target in lung cancer. (2013) (19)
- PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors (2017) (19)
- O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma (2003) (19)
- Abstract 1893: A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer specimens without a matched normal control (2014) (19)
- MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers. (2016) (19)
- Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. (2020) (18)
- 8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer ( (2009) (18)
- Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant (2017) (18)
- Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes. (2017) (18)
- Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling (2018) (17)
- Predictive Biomarkers and Personalized Medicine Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer : Distinct Natural History of Patients with Tumors Harboring the T 790 M Mutation (2011) (17)
- Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors (2019) (17)
- 203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer (2008) (16)
- Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA (2017) (16)
- General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. (2017) (16)
- Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS (2008) (16)
- Metabolic phenotypes of retinoic acid and the risk of lung cancer. (1996) (16)
- BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations (2009) (16)
- Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. (2013) (16)
- Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions (2020) (16)
- Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms (2020) (16)
- Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer (1997) (15)
- Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1. (2016) (15)
- Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) (2014) (15)
- Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP). (2016) (15)
- Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia (2017) (15)
- Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP). (2017) (15)
- Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. (1999) (15)
- Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. (2019) (15)
- Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC). (2017) (14)
- Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib (2014) (14)
- Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP). (2016) (14)
- Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. (2006) (14)
- Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. (2017) (14)
- Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule (2004) (13)
- Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion. (2017) (13)
- Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC (2018) (13)
- Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. (2016) (13)
- FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape (2019) (13)
- A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib (2014) (13)
- Targeting lethal minimal residual disease in small cell lung cancer. (2003) (13)
- Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib (2008) (13)
- A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer (2007) (13)
- Erlotinib in lung cancer. (2005) (12)
- Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations. (2009) (12)
- Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. (2014) (12)
- EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. (2008) (12)
- Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus (2017) (12)
- Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring FGF Amplifications. (2018) (12)
- The Exceptional Responders Initiative: Feasibility of A National Cancer Institute Pilot Study. (2020) (12)
- Identification of a novel fusion TBL1XR1–PDGFRB in a patient with acute myeloid leukemia harboring the DEK–NUP214 fusion and clinical response to dasatinib (2017) (12)
- The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA (2019) (12)
- Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer. (2015) (12)
- BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies. (2017) (12)
- 1170PAnalysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs) (2017) (11)
- Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. (1999) (11)
- Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden (2018) (11)
- Docetaxel in the management of advanced non-small cell lung cancer. (1998) (11)
- 1139PDAnalyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database (2017) (10)
- TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. (2017) (10)
- Predictive Biomarkers and Personalized Medicine Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T 790 M Mutation Using a Locked Nucleic Acid-Based Assay (2011) (10)
- A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy (2015) (10)
- Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer. (2006) (10)
- Personalized, molecularly matched combination therapies for treatment-na. (2017) (10)
- Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma (2017) (10)
- Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy (2015) (10)
- Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling. (2016) (10)
- Targetable BRAF and RAF1 alterations in advanced pediatric cancers. (2020) (10)
- EGFR mutation, immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC (2005) (10)
- Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. (2017) (10)
- Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI). (2010) (10)
- Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma (2017) (9)
- FDA regulation of laboratory-developed tests. (2016) (9)
- Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance. (2011) (9)
- 849PDComparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC) (2017) (9)
- Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy. (2015) (9)
- Successful treatment of a patient with Li–Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib (2014) (9)
- Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer (2018) (9)
- P3-136: A Phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations (2007) (9)
- Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations. (2017) (9)
- 1701OComprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas (2017) (8)
- Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer. (1999) (8)
- Introduction: Small cell lung cancer—A frustrating disease (2003) (8)
- Trials of vinorelbine and docetaxel in the treatment of advanced non small-cell lung cancer. (2000) (8)
- Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. (2021) (8)
- Optimizing therapy in previously treated non-small cell lung cancer. (2006) (8)
- Immunogenicity of a Fucosyl-GM 1-Keyhole Limpet Hemocyanin Conjugate Vaccine in Patients with Small Cell Lung Cancer 1 (1999) (8)
- Abstract S3-6: Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease (2012) (8)
- Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas (2021) (8)
- Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. (2015) (8)
- Comparing two assays for clinical genomic profiling: the devil is in the data (2015) (8)
- Phase I study of the antifolate pralatrexate given with vitamin B12 and folic acid supplementation in patients (pts) with advanced non-small cell lung cancer (NSCLC) (2007) (8)
- Development and validation of a real-world clinicogenomic database. (2017) (8)
- Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. (2012) (7)
- A pan-cancer landscape analysis reveals a subset of endometrial stromal and pediatric tumors defined by internal tandem duplications of BCOR. (2018) (7)
- Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). (2009) (7)
- WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. (2018) (7)
- Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma Specimens (2020) (7)
- “Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer,” (2004) (7)
- Kinase fusions in colorectal cancers: A unique biologic subset. (2018) (7)
- Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors. (2015) (7)
- Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program. (2003) (7)
- Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer. (2017) (7)
- Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP). (2015) (7)
- Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. (2004) (7)
- Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. (2018) (7)
- Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). (1995) (7)
- Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial. (1997) (7)
- Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors (2021) (7)
- Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. (2017) (7)
- EGFR mutations in men and cigarette smokers with lung adenocarcinoma. (2010) (7)
- Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples. (2013) (7)
- Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations. (2015) (7)
- Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. (2014) (6)
- Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma (2016) (6)
- Large-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of BRAF Alterations and Case Report of a BRAF Non-V600-Mutated Tumor Responding to Targeted Therapy. (2018) (6)
- Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma (2008) (6)
- Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB. (2016) (6)
- A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). (2012) (6)
- Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development. (2019) (6)
- Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors (2016) (6)
- A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations. (2009) (6)
- Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies (2016) (6)
- Oral cisapride for the control of delayed vomiting following high-dose cisplatin (1999) (6)
- Phase II study of induction and adjuvant bevacizumab in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) receiving induction docetaxel and cisplatin. (2009) (6)
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017) (6)
- O-187 Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in Non-Small Cell Lung Cancer (NSCLC) patients after prior chemotherapy (2005) (6)
- Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive bladder cancer (MIBC). (2014) (6)
- BRAF: An emerging target for triple-negative breast cancer. (2017) (6)
- Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. (2020) (6)
- O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma (2005) (6)
- Frequency of MET amplification determined by comprehensive next-generation sequencing (NGS) in multiple solid tumors and implications for use of MET inhibitors. (2013) (6)
- Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification (2015) (6)
- Penile and uterine cervical squamous cell carcinomas: A comparative genomic profiling study. (2019) (5)
- Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. (2019) (5)
- Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors (2015) (5)
- Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience (2020) (5)
- The development of docetaxel (Taxotere) in non-small cell lung cancer. (1997) (5)
- 1138PDImmune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC) (2017) (5)
- Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling (2014) (5)
- 54 The epidermal growth factor receptor tyrosine kinase inhibitor, eriotinib (Tarceva TM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: interim results of a phase II trial (2003) (5)
- Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study. (2017) (5)
- Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion (2018) (5)
- CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays. (2017) (5)
- Randomized phase II trial comparing trastuzumab plus weekly docetaxel versus trastuzumab plus weekly paclitaxel in previously untreated advanced non-small cell lung cancer (NSCLC) (2000) (5)
- Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma (2021) (5)
- C-kit protein expression in tumor specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer (SCLC): A phase II clinical trial. (2004) (5)
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma (2014) (5)
- OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D (2017) (5)
- Atypical RAS Mutations in Metastatic Colorectal Cancer. (2019) (5)
- Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms. (2020) (5)
- A case of advanced infantile myofibromatosis harboring a novel MYH10‐RET fusion (2017) (5)
- Segal and Dowsett , p . 1724 Emergence of Constitutively Active Estrogen Receptor-a Mutations in Pretreated Advanced Estrogen Receptor – Positive Breast Cancer (2014) (5)
- Comprehensive Genomic Profiling of Epithelial Ovarian Cancer by Next Generation Sequencing-Based Diagnostic Assay Reveals New Routes to Targeted Therapies (2013) (5)
- Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study. (2004) (5)
- Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma. (2019) (5)
- Improving evidence developed from population‐level experience with targeted agents (2015) (5)
- P2.03b-068 The Druggable Mutation Landscape of Lung Adenocarcinoma: Topic: Biomarkers (2017) (5)
- Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions. (2019) (5)
- Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate. (2016) (4)
- MA16.05 MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP) (2018) (4)
- Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies. (2015) (4)
- Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study (2021) (4)
- Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI. (2011) (4)
- Lung Cancer Fluorescence In Situ Hybridization , Immunohistochemistry , and Next-Generation Sequencing for Detection of EML 4-ALK Rearrangement in Lung Cancer (2015) (4)
- A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer (2007) (4)
- Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes (2016) (4)
- Ifosfamide Plus High‐Dose Cisplatin in Patients with Non‐Small Cell Lung Cancer Previously Treated with Chemotherapy (1995) (4)
- PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment. (2018) (4)
- O-207 Collateral damage from the lung cancer explosion in American women: Has sex migration replaced stage migration as a confounding factor in lung cancer trials? (2003) (4)
- Comprehensive genomic profiling of ctDNA in patients with colon cancer and its fidelity to the genomics of the tumor biopsy. (2018) (4)
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) (4)
- Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231]. (2019) (4)
- Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients. (2013) (4)
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. (2020) (4)
- Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP). (2018) (4)
- OA 12.08 Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) Cases with Focal and Non-Focal MET Amplification (2017) (4)
- Erratum for the research article: Genomic proling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (Science Translational Medicine DOI: 10.1126/scitranslmed.aai7993) (2019) (4)
- Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies. (2016) (4)
- Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response (2019) (4)
- Molecular landscape of BRAF mutations in large cell neuroendocrine carcinoma of lung: An analysis of BRAF mutations and a case report of a BRAF non-V600E mutated tumor responding to targeted therapy. (2017) (4)
- Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung (2005) (4)
- Phase I/II study of ABI-007 as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). (2006) (4)
- Potentially actionable kinase fusions in inflammatory myofibroblastic tumors. (2013) (4)
- Clinical application of comprehensive next-generation sequencing-based genomic profiling for identification of actionable genomic alterations in pediatric solid tumors and hematolymphoid malignancies: The Foundation Medicine pediatric experience. (2014) (4)
- Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib (2005) (4)
- 1700OGenomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types (2017) (4)
- O-241 Clinical, pathologic, and molecular characteristics of NSCLC patients sensitive to gefitinib (2003) (4)
- Genomic alterations (GA) predicted to confer lack of benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 HER2-amplified (HER2amp) cases. (2018) (4)
- BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). (2014) (4)
- Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing. (2017) (4)
- Patient Derived Xenograft (PDX) Models Recapitulate the Genomic-Driver Composition of Acute Leukemia Samples (2014) (3)
- Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. (2019) (3)
- Pan-cancer assessment of BRCA1/2 genomic alterations (GAs) by comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA). (2018) (3)
- Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform (2013) (3)
- Targeted therapy for HER2 driven colorectal cancer. (2017) (3)
- OA10.01 Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade (2017) (3)
- Abstract 4261: Prospective next generation sequencing (NGS) of rare or poor prognosis cancers (2014) (3)
- Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load. (2016) (3)
- Frequency of actionable genomic alterations in early-stage lung adenocarcinoma (LA) detected by next-generation sequencing (NGS). (2012) (3)
- Abstract PD02-07: Next-generation sequencing of FFPE breast cancers demonstrates high concordance with FISH in callingHER2amplifications and commonly detects other clinically relevant genomic alterations (2012) (3)
- Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay (2013) (3)
- Next-generation sequencing (NGS) to identify actionable genomic changes in common and rare solid tumors: The FMI experience with the initial 50 consecutive patients. (2012) (3)
- Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression (2016) (3)
- Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation. (2015) (3)
- MSI-H testing via hybrid capture based NGS sequencing of liquid biopsy samples. (2019) (3)
- 3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer (2015) (3)
- Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma. (2016) (3)
- Genomic alterations in colitis-associated cancers in comparison to those found in sporadic colorectal cancer and present in precancerous dysplasia. (2020) (3)
- Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset. (2017) (3)
- Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC). (2017) (3)
- Using patients as their own controls for cost evaluation of phase I clinical trials. (2004) (3)
- MSI-high and MSI-stable colorectal carcinomas (CRC): A comprehensive genomic profiling (CGP) study. (2018) (3)
- BRAF genomic alterations in breast cancer (2016) (3)
- Genomic Landscape of Adult and Pediatric BCR-ABL1-Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing. (2018) (3)
- Comparison of comprehensive genomic profiling (CGP) and hotspot next generation sequencing (NGS) assays in identifying treatment options for care of patients with metastatic cancer in in the community setting. (2016) (3)
- RICTOR Amplifi cation Defi nes a Novel Subset of Patients with Lung Cancer Who May Benefi t from Treatment with mTORC 1 / 2 Inhibitors (2015) (3)
- Comprehensive pan-cancer analysis of KRAS genomic alterations (GA) including potentially targetable subsets (2019) (3)
- Genomic profiling of squamous malignancies across anatomic sites. (2017) (3)
- Identification of novel fumarate hydratase gene alterations in prostate cancer. (2017) (3)
- MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation. (2019) (3)
- Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of the urinary bladder. (2017) (3)
- Pan-cancer genomic landscape of the cyclin D1/FGF3,4,19 (11q13) amplicon including associations with HPV status, and ESR1 and AR alterations (2019) (3)
- Human Cancer Biology Relapsed Classic E-Cadherin ( CDH 1 ) – Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER 2 ( ERBB 2 ) Gene Mutations (2013) (3)
- Frequency of genomic biomarkers of response to immunotherapy in sarcoma. (2018) (3)
- Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations. (2015) (3)
- Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. (2010) (2)
- Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC). (2017) (2)
- Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load (2016) (2)
- The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD 1839 Selectively Potentiates Radiation Response of Human Tumors in Nude Mice , with a Marked Improvement in Therapeutic Index 1 (2003) (2)
- Case Presentation Alk Fusions Are Also Associated with Younger Age Next-generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib- Sensitive Alk Rearrangement in a Patient with Metastatic Non–small-cell Lung Cancer (2012) (2)
- MHC-1 genotype as a predictor of response to immunotherapy. (2019) (2)
- Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor (2016) (2)
- Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology (2022) (2)
- Comprehensive genomic profiling (CGP) to assess mutational load in gastric and esophageal adenocarcinomas: Implications for immunotherapies. (2016) (2)
- Comprehensive genomic sequencing of prostate sarcomatoid carcinoma tumors identifies differences in genomic alterations compared to prostate adenocarcinoma tumors. (2017) (2)
- Comprehensive Genomic Profiling of Uterine Leiomyosarcomas Identifies Frequent Clinically Relevant Genomic Alterations and Opportunities for Personalized Therapies (2016) (2)
- MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC (2017) (2)
- Next-generation sequencing of genomic and cDNA to identify a high frequency of kinase fusions involving ROS1, ALK, RET, NTRK1, and BRAF in Spitz tumors. (2013) (2)
- Abstract LB-178: Genomic profiling of 1239 diverse pediatric cancers identifies novel discoveries across tumors (2016) (2)
- A Phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations: P3-136 (2007) (2)
- 1169PTopography of Tumor Mutational Burden (TMB) and Immune-related Genomic Alterations (GA) Across Gastrointestinal Malignancies (GIm): A Study of 22,570 Cases (2017) (2)
- Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study. (2019) (2)
- Abstract 4670: A novel companion diagnostic predicts response to the PARP inhibitor rucaparib in ovarian cancer (2015) (2)
- Abstract P6-03-12: Comprehensive genomic profiling of clinically advanced mucinous carcinoma of the breast (2016) (2)
- Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history. (2014) (2)
- Abstract S3-06: Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer (2013) (2)
- Extensive High-Depth Sequencing Of Longitudinal CLL Samples Identifies Frequent Mutations In MAP Kinase Signaling and Novel Mutations Activating Notch and Beta-Catenin (2013) (2)
- Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation (2020) (2)
- 9086 Pralatrexate plus vitamin B12 and folic acid supplementation in patients with previously-treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial (2009) (2)
- An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC). (2013) (2)
- Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma (2014) (2)
- PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy. (2018) (2)
- Extra-mammary Paget’s disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study. (2019) (2)
- Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets (2017) (2)
- Abstract PD3-05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth (2019) (2)
- Measurements of total DNA and methylated tumor suppressor genes in the plasma of patients with metastatic non-small cell lung cancer (NSCLC) before, and after chemotherapy, as potential biomarkers for response to treatment (2005) (2)
- Abstract 1775: The interaction of PD-L1, TMB, and genomic alterations in NSCLC (2017) (2)
- A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations (2007) (2)
- MA 12.03 Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) (2017) (2)
- 319 Genomic profiling of uterine leiomyosarcomas reveal frequent alterations in Akt/mammalian target of rapamycin (mTOR) pathway genes and other actionable genomic abnormalities linked to targeted therapies (2014) (2)
- 727 Inhaled retinoids for the prevention of respiratory tract cancers (1997) (2)
- 1OComprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types (2017) (2)
- Erratum: Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity (Cancer Cell (2019) 36(4) (444–457.e7), (S1535610819303848), (10.1016/j.ccell.2019.09.001)) (2020) (2)
- Precision medicine: Preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT 2) study (2019) (2)
- Current Role of Irinotecan in the Treatment of Non-Small-Cell Lung Cancer (2002) (2)
- HER2 Amplifi cation: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR (2012) (2)
- Identification of genomic markers of sensitivity and resistance to checkpoint inhibitors in non-small cell lung cancer in a real world clinico-genomic database. (2018) (2)
- Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA). (2016) (2)
- Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer. (2019) (2)
- Abstract 2987: Validation and clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) (2017) (2)
- Immunotherapy predictive biomarkers in metastatic breast cancer (MBC). (2019) (2)
- Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence. (2016) (2)
- Targeted treatment of RAI-resistant metastatic thyroid cancer postcomprehensive genomic profiling. (2014) (2)
- Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI‐1)–Deficient Carcinomas of the Urinary System (2017) (2)
- Genomic Profiling of Cancers of Unknown Primary Site--Reply. (2015) (2)
- Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer. (2013) (2)
- Response to EGFR TKIs in never smokers with stage IV EGFR mutant squamous cell carcinoma of the lung (SQCC). (2011) (2)
- Abstract S1-08: Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival (2015) (2)
- Melanoma BRAF Fusions—Response (2014) (2)
- Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications. (2014) (2)
- Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment? (2008) (2)
- Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC). (2012) (2)
- Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations (2019) (2)
- Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors (2020) (2)
- Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML (2013) (2)
- Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options. (2015) (2)
- Abstract 4298: Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer (2015) (2)
- Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis (2015) (1)
- Distinct age-associated genomic profiles in acute myeloid leukemia (AML) using FoundationOne heme. (2016) (1)
- BRCA1/2 reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples. (2017) (1)
- Association of tumor mutational burden in cutaneous squamous cell carcinoma with genomic alterations in Notch family receptors. (2017) (1)
- Occurrence of ALK fusions in cancers other than non-small cell lung cancer in a wide variety of tumor types and response to anti-ALK targeted therapy. (2017) (1)
- Refractory testicular pure seminoma (PS) and non-seminomatous(NS) germ cell tumors (GCT): A comprehensive genomic profiling (CGP) study. (2018) (1)
- Mutational landscape of metastatic cancers discovered from prospective clinical sequencing at community practice cancer program. (2018) (1)
- An analysis of ERBB2 alterations (amplifications and mutations) found by next-generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients. (2013) (1)
- Biomarkers of immune checkpoint inhibitor response in metastatic breast cancer: PD-L1 protein expression, CD274 gene amplification, and total mutational burden. (2016) (1)
- Abstract A23: Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: The Foundation Medicine (FMI) experience (2014) (1)
- Abstract 497: Understanding oncogenic fusions: Lessons learned from inflammatory myofibroblastic tumor (2015) (1)
- Comparative genomic profiling (CGP) of refractory/metastatic penile (mPSCC) and non-penile cutaneous squamous cell carcinoma (mCSCC). (2018) (1)
- MA04.09 RICTOR Amplification in Non-Small Cell Lung Cancer: An Emerging Therapy Target (2017) (1)
- Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC). (2017) (1)
- Abstract PD3-1: Serial next generation sequencing (NGS) of poor prognosis luminal tumors across treatment history reveals both de novo and acquired alterations potentially associated with endocrine resistance (2013) (1)
- Screening for EGFR, KRAS, and PIK3CA mutations in well-characterized, immunohistochemically confirmed squamous cell carcinoma of lung. (2011) (1)
- Phase I and Pharmacokinetic Study of 10-Propargyl-10-deazaaminopterin , a New Antifolate 1 (2000) (1)
- Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms (2013) (1)
- Comprehensive genomic profiling to identify recurrent kinase fusions in pancreatic ductal adenocarcinoma. (2018) (1)
- C-kit protein expression in tumor specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer (SCLC): A phase II clinical trial (2004) (1)
- Analysis of over 100,000 patients with cancer for CD274 (PD-L1) amplification: Implications for treatment with immune checkpoint blockade. (2018) (1)
- Abstract A28: Clinical next-generation sequencing (NGS) reveals genomic alterations (GAs) to guide targeted therapy in advanced neuroblastoma patients (2014) (1)
- Primary pulmonary sarcomas (PSRC): A comprehensive genomic profiling (CGP) study. (2018) (1)
- MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates (2017) (1)
- TMPRSS-ERG fusion in men with prostate cancer (PCa) and non-prostate malignancies: Defining a role for comprehensive genomic profiling (CGP) to guide clinical care. (2016) (1)
- Next-generation sequencing (NGS) in relapsed/refractory triple-negative breast cancer (TNBC) in Israel. (2014) (1)
- Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC). (2018) (1)
- Abstract 1607: AnERBB2follow-on companion diagnostic for clinical care of patients with breast cancer (2018) (1)
- Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management (2015) (1)
- Abstract 1897: RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer (2012) (1)
- Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations. (2014) (1)
- Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer (2016) (1)
- Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy. (2018) (1)
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations. (2015) (1)
- Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung (2005) (1)
- Abstract PR04: BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. (2013) (1)
- Feasibility of collaborative precision medicine oncology between academic- and community-based hospitals. (2017) (1)
- P3.02c-024 Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling: Topic: Targeted Therapy (2017) (1)
- RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC). (2017) (1)
- Concordance of driver mutations in primary and matched metastasis from patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS). (2012) (1)
- Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study. (2019) (1)
- Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway. (2015) (1)
- Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP) (2016) (1)
- Comprehensive genomic profiling of parathyroid carcinoma. (2017) (1)
- 194OHybrid-capture based comprehensive genomic profiling of hepatocellular carcinoma identifies patients who may benefit from targeted therapies and immune checkpoint blockade (2017) (1)
- Docetaxel (TaxotereS) in the management of advanced non-small cell lung cancer (NSCLC) (1997) (1)
- Prediction and Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin (COO) Subtypes Using Genomic Features from Targeted Next-Generation Sequencing (2018) (1)
- P3.13-26 Outcomes of Patients with Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board (2018) (1)
- OA 18.03 Genomic Profiling Reveals Hedgehog Pathway Alterations in Vismodegib Sensitive Lung Squamous Cell Carcinoma (2017) (1)
- Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT). (2018) (1)
- Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC). (2018) (1)
- Abstract A79: Comprehensive genomic profiling (CGP) of adult granulosa cell tumors (aGCT) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options (2015) (1)
- Abstract 4544: A validated diagnostic assay for identifying ovarian cancer patients with deleterious BRCA mutations and high genomic loss of heterozygosity (LOH) (2018) (1)
- Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. (2016) (1)
- Comprehensive genomic profiling to identify tumor mutational burden (TMB) as an independent predictor of response to immunotherapy in diverse cancers. (2017) (1)
- Phase I study of the anitfolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC) (2007) (1)
- PATH-20. COMPREHENSIVE GENOMIC PROFILING COMPARING PRIMARY CNS LYMPHOMA TO SYSTEMIC DIFFUSE LARGE B CELL LYMPHOMA REVEALS BIOMARKERS INDICATING POTENTIAL BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS (2017) (1)
- Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies (2016) (1)
- Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (2013) (1)
- Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced cancers of the GI tract and anus. (2017) (1)
- MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant (2017) (1)
- P2.02-016 Pulmonary Sarcomas: A Comprehensive Genomic Profiling Study (2017) (1)
- Abstract P6-03-02: EGFR genomic alterations in 5,605 cases of refractory and metastatic breast cancer (2016) (1)
- Comprehensive genomic profiling of 298 lung cancers of varying histologies harboring MET exon 14 alterations. (2016) (1)
- Abstract 4268: An unbiased survey of cancer-related rearrangements in 5,917 solid tumors identifies therapeutically actionable fusions across multiple disease subtypes (2014) (1)
- Abstract 4699: Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test (2014) (1)
- O-154 Development of a tetravalent small cell lung cancer (SCLC) vaccine containing GM2, fucosyl GM1, Globo H, and polysialic acid (2003) (1)
- Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era. (2016) (1)
- Landscape of RAF1 fusions in solid tumors and therapeutic utility of sorafenib (2016) (1)
- Malignant pheochromocytoma: A comprehensive genomic profiling study. (2019) (1)
- Abstract CT053: High rates of personalized molecular matching are achievable in a precision oncology navigation trial: the I-PREDICT study (2017) (1)
- Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). (2020) (1)
- SMARCA4 deficient non-small cell lung cancer (NSCLC): A comprehensive genomic profiling (CGP) study (2019) (1)
- Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP): Actionable genomic alterations (GA) and new routes to targeted therapies. (2014) (1)
- Clinical next generation sequencing (NGS) of fine needle aspiration (FNA) biopsies in non-small cell lung (NSCLC) and pancreatic cancers. (2013) (1)
- Abstract S6-01: JAK2 amplifications are enriched in triple negative breast cancers (TNBCs) after neoadjuvant chemotherapy and predict poor prognosis (2013) (1)
- Abstract P2-12-01: Comprehensive genomic profiling of 34 cases of breast angiosarcoma (2017) (1)
- PIK 3 CA C 2 domain deletions hyperactivate phosphoinositide 3-kinase ( PI 3 K ) , generate oncogene dependence and are exquisitely sensitive to PI 3 Kα inhibitors (2017) (1)
- Reproducibility of computed tomography (CT) measurements of lung cancer (2008) (1)
- PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas. (2020) (1)
- MA04.01 Non-Amplification Mutation of ERBB2 in EGFR-Mutated Lung Cancer (2017) (1)
- High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer. (1996) (1)
- Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors. (2018) (1)
- Abstract B16: Validation and clinical feasibility of a Foundation Medicine assay to identify immunotherapy response potential through tumor mutational burden (TMB) (2017) (1)
- A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments (2016) (1)
- Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors. (2016) (1)
- Docetaxel (Taxotere®) in the management of advanced non-small cell lung cancer (NSCLC) (1997) (1)
- Juliann Chmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR-Mutant Non (2011) (1)
- Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study. (2018) (0)
- Frequency of clinically relevant genomic alterations using comprehensive genomic profiling (CGP) for the management of advanced gynecologic malignancies in a community setting. (2015) (0)
- P1.01-23 Retrospective Analysis of Real-World Clinico-Genomic Data for Clinical Impact of Genomic Profiling of ctDNA in NSCLC (2019) (0)
- Comprehensive genomic profiling (CGP) of advanced nonseminomatous testicular germ cell tumors (NSGCT) to reveal clinically relevant genomic alterations (CRGA) to guide targeted therapy. (2016) (0)
- Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study. (2018) (0)
- Predictive and Prognostic Significance of Comprehensive Genomic Profiling in Patients with Diffuse Large B-Cell Lymphoma (2015) (0)
- Abstract P2-03-06: FoundationOne profiling of TSC1 and TSC2-mutated advanced breast cancers (2015) (0)
- Tumors Harbor Multiple Potentially Actionable Kinase Fusions (2014) (0)
- MP37-10 REFRACTORY TESTICULAR PURE SEMINOMA (PS) AND NON-SEMINOMATOUS(NS) GERM CELL TUMORS (GCT): A COMPREHENSIVE GENOMIC PROFILING (CGP) STUDY (2018) (0)
- Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy. (2017) (0)
- P1.02-061 Kinase Fusions in Non-Small Cell Lung Carcinoma Identified by Hybrid Capture Based ctDNA Assay: Topic: Driver Genes in NSCLC, Resistance, and Other (2017) (0)
- RAS-amplified colorectal cancers: Microsatellite stability status, RAS/BRAF mutations, and prediction of anti-EGFR resistance. (2019) (0)
- Abstract P1-05-07: Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation ofNF1and other genes associated with PI3K and RAS pathway activation (2017) (0)
- LYMPHOID NEOPLASIA Integrated genomic DNA/RNA pro fi ling of hematologic malignancies in the clinical setting (2016) (0)
- [Tamoxifen or tamoxifen in combination with chemotherapy in adjuvant therapy of breast carcinoma. Results of a multicenter randomized study]. (2001) (0)
- Comprehensive genomic profiling (CGP) of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors (PMNSGCT). (2018) (0)
- Unique pattern of metastasis to the adenexa in ALK rearranged non-small cell lung cancer. (2014) (0)
- Genomic profiling of diffuse gastric carcinoma (DGC). (2019) (0)
- Bronchioloalveolar Carcinoma of the Lung (2006) (0)
- Pathobiology (2011) (0)
- Acknowledgement to reviewers (2015) (0)
- Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations (2015) (0)
- Comprehensive genomic profiling of lung cancer cytologic specimens obtained by guided fine-needle aspirate biopsies. (2018) (0)
- Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling. (2013) (0)
- 464 Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sensitive to MET inhibitors (2015) (0)
- Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation. (2018) (0)
- Comprehensive genomic profiling of ovarian carcinomas identifies both ERBB2 amplifications and activating point mutations as biomarkers for anti-HER2 targeted therapy (2016) (0)
- Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity (2020) (0)
- Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study. (2018) (0)
- A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice NEILVASAN, a ROMANYELENSKY, b KAIWANG, b STACYMOULDER, c HANNAHDZIMITROWICZ, a RONIAVRITSCHER, c BALIANGWANG, c (2014) (0)
- APhase 1 Study of Pralatrexate in Combinationwith Paclitaxel or Docetaxel in Patients with Advanced SolidTumors (2007) (0)
- 2879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinoma (2015) (0)
- Comprehensive genomic profiling of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC). (2015) (0)
- Abstract P6-07-06: Clinicopathologic characterization and comprehensive genomic profiling (CGP) of advanced breast cancer patients with fibroblast growth factor receptor (FGFR) alterations (2016) (0)
- Abstract 2415: Development of a clinical cell-free DNA assay for cancer molecular profiling (2015) (0)
- Genomic analysis of colitis-associated cancers. (2015) (0)
- B08 Impact of Concurrent STK11 Loss and c-MYC Amplification in Metastatic Non-Small Cell Lung Cancer (NSCLC) (2020) (0)
- Smoking history and frequency of somatic KRAS mutations in adenocarcinoma of the lung (2007) (0)
- 801 Therapeutically relevant extracellular domain mutations in ERBB2/HER2 are observed across multiple tumor types and are sssociated with major responses to anti-HER2 targeted therapies (2015) (0)
- Comprehensive Genomic Profiling and Precision Pathology for Clinically Advanced Salivary Gland Myoepithelial Carcinoma (2018) (0)
- Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA). (2018) (0)
- Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes. (2015) (0)
- ComprehensiveGenomicProfilingofAdvancedEsophagealSquamous CellCarcinomasandEsophagealAdenocarcinomasRevealsSimilarities and Differences (2015) (0)
- MA 15.06 ERBB Receptor Feedback Inhibitor-1 Alterations in Non-Small Cell Lung Cancer (2017) (0)
- Genomic Profiling Combining DNA and RNA Analysis of 112 Formalin-Fixed Paraffin-Embedded Diffuse Large B Cell Lymphoma Specimens Identifies a High Frequency of Clinically Relevant Genomic Alterations (2014) (0)
- Abstract P1-05-08: Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression (2017) (0)
- Abstract P6-07-04: Comprehensive genomic profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy (2017) (0)
- Comprehensive Genomic Profiling Reveals Complex and Distinct but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials (2018) (0)
- Overview Of The Genomic Landscape Of High Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA Sequencing (2013) (0)
- Abstract A80: Clinical evaluation of patients with advanced solid tumors harboring ERBB2-somatic mutations (2015) (0)
- FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape. (2019) (0)
- Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket (2015) (0)
- IA30 Investigating and Overcoming Primary Resistance of EGFR and HER2 (ERBB2) Exon 20 Mutant NSCLC (2020) (0)
- Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC). (2018) (0)
- Abstract 2337: Pan-cancer analysis of sex differences and their associations with ancestry and genomic biomarkers in a large comprehensive genomic profiling dataset (2020) (0)
- Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis (2015) (0)
- BRCA1/2 reversion mutations in pancreatobiliary cancer identified from patient biopsies. (2017) (0)
- Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC. (2022) (0)
- Erratum: Triple-negative breast cancers with amplication of JAK2 at the 9p24 locus demonstrate JAK2-specic dependence (Science Translational Medicine (2019) 11, 476, (eaaw6162), 10.1126/scitranslmed.aaw6162) (2019) (0)
- Abstract 1774: Selection for the EGFR T790M gatekeeper resistance mutation may vary among different small molecule EGFR TKIs (2010) (0)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (0)
- CARCINOMAS OF THE RENAL MEDULLA: A COMPREHENSIVE GENOMIC PROFILING (CGP) STUDY: PD46‐02 (2018) (0)
- Abstract 3570: Development and validation of a clinical next generation sequencing-based assay for hematologic malignancies (2014) (0)
- Abstract A46: Identification of NTRK fusions in pediatric tumors via comprehensive genomic profiling (2016) (0)
- Comprehensive genomic profiling (CGP) of esophageal and tubular GI tumors to identify frequencies of ErbB family member amplification with therapeutic implications. (2017) (0)
- Therapeutic insights for malignant phyllodes from next-generation sequencing. (2014) (0)
- Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC). (2018) (0)
- MA03.05 BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer (2019) (0)
- 240PDComprehensive genomic profiling of primary and metastatic CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas reveals markers of hormonal therapy resistance and opportunities for targeted therapies (2017) (0)
- 2651 Comprehensive genomic profiling (CGP) identifies unique and abundant clinically relevant genomic alterations in rare histologies of renal cell carcinoma (2015) (0)
- Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers. (2016) (0)
- On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer (2021) (0)
- Front & Back Matter (2012) (0)
- Companion Diagnostics and Cancer Biomarkers Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer (2014) (0)
- 2641 Comprehensive genomic profiling of advanced penile carcinoma suggests a high rate of clinically relevant genomic alterations (2015) (0)
- Comprehensive Hybrid Capture-Based Genomic Profiling of T-Cell Leukemias and Lymphomas Reveals Targetable JAK1 and JAK3 Co-Existing Mutations (2014) (0)
- Intratumoral heterogeneity of cancer driver genomic alterations across several tumor types. (2015) (0)
- Comprehensive Genomic Profiling (CGP) Identifies Novel BCL6 Rearrangements in Diverse Subtypes of Non-Hodgkin Lymphoma (NHL) As Well As Known Rearrangements Not Detected Using Standard of Care (SOC) Assays (2017) (0)
- Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel. (2014) (0)
- How do I treat a patient with newly diagnosed lung adenocarcinoma (2011) (0)
- Genetic Alterations and Tumor Mutation Burden of Poorly Differentiated Small Cell Euro-endocrine Carcinomas are Similar in Lung Lesions and Distant Metastatic Foci (2018) (0)
- Genomic Characteristics Clinical Phenotype and Disease Course of TP53 Mutated Diffuse Large B Cell Lymphoma at Diagnosis and Relapse (2017) (0)
- Comprehensive genomic sequencing of appendiceal cancer tumors to identify different genomic alterations by subtype, novel treatment opportunities, and improved outcomes. (2017) (0)
- Commentary on Abstracts #976, #1008, and #1964 (2000) (0)
- Commentary on Abstract #1890 (2000) (0)
- Comprehensive genomic profiling (CGP) of gynecologic malignancies in Israeli population to reveal potentially clinically relevant genomic alterations and opportunities for targeted therapies. (2015) (0)
- The diagnostic puzzle of ALK rearrangement in lung cancer. A novel intron related abnormality (2013) (0)
- Characterization of mutational load in patients with advanced urothelial cancer. (2016) (0)
- Comprehensive genomic profiling of hematologic malignancies by a clinical next generation sequencing-based assay (2013) (0)
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma (2018) (0)
- MP69-09 MALIGNANT PHEOCHROMOCYTOMA: A COMPREHENSIVE GENOMIC PROFILING STUDY (2019) (0)
- Investigating the Utility of comprehensive genomic Profiling for patients with newly diagnosed breast cancer. (2016) (0)
- Landscape of FMS-like tyrosine kinase 3 (FLT3) and associated molecular alterations in 44,766 gastrointestinal (GI) cancers. (2019) (0)
- PUB105 Hybrid-Capture Based Comprehensive Genomic Profiling Detects EGFR Point Mutations in >20% of Patients Missed by Standard of Care Testing (2017) (0)
- Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia (2019) (0)
- Abstract 4737: Comprehensive profiling of immunoglobulin sequences using hybrid capture-based next generation sequencing in B-cell hematologic malignancies (2015) (0)
- 1217PDComprehensive genomic profiling (CGP) and tumor mutational burden (TMB) assessment in subtypes of metastatic melanoma (2017) (0)
- P3.02-062 An EGFR Follow-On Companion Diagnostic for Clinical Care of Patients with NSCLC (2017) (0)
- Abstract 2033: Identification of a novel genetic abnormality, the amplification of rictor (rapamycin-insensitive companion of mTOR), in a patient with non-small cell lung cancer. (2013) (0)
- Genomic profiling of small bowel adenocarcinoma: Insights from a comparative analysis with gastric and colorectal cancer and opportunities for targeted therapy (2016) (0)
- Personalized Treatment for a Patient with a BRAF V600E-Mutation Using Dabrafenib and Tumor Treatment Fields (TTFields; NovoTTF -100A) Device in a Glioblastoma Arising from Ganglioglioma (P3.280) (2016) (0)
- Cancer Positive Breast − in Pretreated Advanced Estrogen Receptor Mutations α Emergence of Constitutively Active Estrogen Receptor-Updated (2014) (0)
- Contents Vol. 90, 2016 (2016) (0)
- Choroid plexus tumors of the central nervous system: Searching for therapy targets with comprehensive genomic profiling. (2018) (0)
- P3.02-061 An ALK Follow-On Companion Diagnostic Using CGP for Clinical Care of Patients with NSCLC (2017) (0)
- High-Throughput Mutational Profiling Of Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia Reveals Frequent Mutations In NRAS In JAK2V617F-Negative Post-MPN AML (2013) (0)
- O-017 Lung adenocarcinomas with mutations in EGFR and KRAS havedistinct gene expression profiles (2005) (0)
- Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity (2020) (0)
- Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia (2017) (0)
- O-123 A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC (2005) (0)
- Next-generation sequencing (NGS) in metastatic colorectal cancer (CRC) patients (pts) in Israel. (2014) (0)
- Comprehensive genomic profiling (CGP) defines the genomic landscape of colorectal cancer (CRC) in individuals of African ancestry. (2019) (0)
- Identifying the prognostic significance of genomic alterations in a real-world, EHR-derived clinico-genomic database (CGDB). (2018) (0)
- Genomic findings in adenocarcinoma of the urinary bladder. (2019) (0)
- NewChemotherapeutic Agentsfor Non-small CellLungCancer* (2015) (0)
- Latent class analysis of bladder urothelial carcinoma to reveal sub-classes defined by alterations to chromatin and signal transduction networks. (2016) (0)
- FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study. (2018) (0)
- Abstract PD6-5: Profiling of ESR1-mutated metastatic breast cancers by FoundationOne® allows a broad genomic understanding for potential clinical implications (2015) (0)
- Atypical RAS Mutations in Metastatic Colorectal Cancer (2019) (0)
- Comprehensive genomic profiling of salivary gland adenocarcinomas to reveal frequency of druggable targets. (2015) (0)
- How Do I Treat a Patient with Newly Diagnosed Lung Adenocarcinoma and an EGFR Mutation (2011) (0)
- Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors (2013) (0)
- Ductal and acinar carcinomas of the prostate: A comparative comprehensive genomic profiling study. (2019) (0)
- Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas. (2018) (0)
- Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study. (2019) (0)
- Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases. (2018) (0)
- Abstract 417: Comparative analysis of clinically validated NGS-based assays reveals high concordance across short variants (2018) (0)
- 337 Evaluation of the immunogenicity of selected doses of BEC2 plus BCG after initial therapy for small cell lung cancer and report of long survival of immunized patients (1997) (0)
- Abstract B06: Distinct genomic profiles and targetable alterations revealed by FoundationOne® Heme in hematolymphoid malignancies in adolescents and young adults. (2015) (0)
- Rictor amplification to define a novel and unique subset of lung cancer patients. (2014) (0)
- Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay (2015) (0)
- Genomic profiling and precision medicine in 3,745 patients with advanced cancer. (2014) (0)
- Recurrent and metastatic carcinomas of the lacrimal gland: High frequency of ERBB2 driven disease. (2018) (0)
- The art of detecting EML4-ALK gene rearrangements in NSCLC patients - Immediate implications for patient care (2013) (0)
- Amplification of CRKL in human cancer: A rare event associated with potential sensitivity to targeted therapy. (2015) (0)
- 76P Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN1EVE in patients with metastatic renal cell carcinoma (2018) (0)
- P2.02-052 A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care (2017) (0)
- Abstract LB-B02: Detection of Clonal Hematopoiesis of Indeterminate Potential in Solid Tumors: Implications for Interpretation of Molecular Testing (2018) (0)
- Advanced acinic cell carcinoma harbors kinase rearrangements including BRAF kinase domain duplications (2016) (0)
- Abstract 968: Co-occurring genomic alterations define major subsets ofKRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities (2015) (0)
- Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses (2016) (0)
- 250 Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes (2014) (0)
- NovelD761YandCommonSecondary T790MMutationsinEpidermal Growth Factor Receptor^Mutant LungAdenocarcinomaswith AcquiredResistance toKinase Inhibitors (2006) (0)
- A Comprehensive Clinical Next Generation Sequencing-Based Assay Can Impact Hematopathologic Diagnosis in a Significant Subset of Patients with Hematologic Malignancies (2014) (0)
- Comprehensive Genomic Profiling for Improved Diagnosis and Therapy of Pediatric Acute Leukemias (2016) (0)
- Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) – 2011–2015: The challenge of precision medicine in a very broad playing field (2016) (0)
- Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC). (2017) (0)
- Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC). (2019) (0)
- 433PDComprehensive genomic profiling of metastatic and relapsed thyroid gland carcinomas is associated with tumor type and reveals new routes to targeted therapies (2017) (0)
- Anal melanoma: A comparative comprehensive genomic profiling study. (2019) (0)
- Vascular endothelial growth factor trap in non-small cell lung cancer. Discussion (2007) (0)
- Abstract B122: A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. (2013) (0)
- PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study. (2018) (0)
- 1633PDCo-amplification of KIT/KDR/PDGRA in over 100,000 advanced cancer cases (2017) (0)
- Comprehensive genomic profiling (CGP) of advanced stage esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinomas (EAC) to reveal similarities and differences. (2015) (0)
- Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. (2021) (0)
- 116 Phase III trial of docetaxel plus vinorelbine in patients with advanced non-small cell lung cancer☆ (1997) (0)
- High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1 (2016) (0)
- Malignant non-adrenal paraganglioma (mPara) and adrenal pheochromocytoma (mPheo) a comparative comprehensive genomic profiling (CGP) study (2019) (0)
- Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients. (2017) (0)
- Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC). (2018) (0)
- Mutational Profiling Of Myeloid Malignancies For Prediction Of Disease Relapse Following Allogeneic Stem Cell Transplantation (2013) (0)
- Abstract 1694: A multi-institutional, multi-tumor analysis of fine needle aspiration (FNA) cytology smear (FNAC) performance in clinical comprehensive genomic profiling (2019) (0)
- Abstract 1833: Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database (2018) (0)
- Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations. (2016) (0)
- Abstract 2431: Enrichment of targetable mutations in the relapsed neuroblastoma genome (2016) (0)
- Comprehensive Clinical Genomic Profiling Defines Age-Associated Molecular Targets in Pediatric and Adult Acute Myeloid Leukemia (2016) (0)
- Abstract 3394: CGP identifies largely non-overlapping high tumor mutational burden and HRD genomic alterations in 721 clinically advanced prostate acinar adenocarcinoma cases (2017) (0)
- Accelerating clinical trial enrollment with comprehensive genomic profiling (CGP) and just-in-time clinical trial sites: An index case of a paradigm shift. (2017) (0)
- Commentary on Abstracts #2 and #1968 (2000) (0)
- Mutational profiling of the oncogenome in non-small cell lung cancer (NSCLC) (2005) (0)
- Prevalence of microsatellite instability and association with pembrolizumab (P) usage in a real-world clinico-genomic database. (2018) (0)
- Comprehensive genomic profiling reveals recurrent XPO1 mutations and other alterations in archival samples of patients with Hodgkin lymphoma (2016) (0)
- Abstract A32: MCL1 gene amplification in breast cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimen (2016) (0)
- 62 - Shared and Private Genomic Alterations in Colitisassociated Dysplasia and Carcinoma Developing Synchronously within the Same Patient (2018) (0)
- Analysis of EGFR mutant urothelial carcinoma (UC) reveals distinct mutational landscape. (2019) (0)
- Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies. (2018) (0)
- Priority Report D 538 GMutation in EstrogenReceptor-a : ANovelMechanism for Acquired Endocrine Resistance in Breast Cancer (2013) (0)
- A U.S.-based prospective, multi-center, non-interventional study of the role of comprehensive genomic profiling in the clinic. (2015) (0)
- 414 Genomic profiling using a clinical next generation sequencing (NGS) assay reveals genomic alterations to guide targeted therapy in advanced neuroblastoma patients (2014) (0)
- Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases (2019) (0)
- Frequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS). (2013) (0)
- Abstract B091: Vulvar squamous cell carcinoma: Comprehensive genomic profiling of HPV(+) versus HPV(–) forms reveals a different set of potentially actionable biomarkers (2019) (0)
- Comprehensive genomic profiling (CGP) of gall bladder adenocarcinoma (GBAC) in patients from distinct ancestral populations (2019) (0)
- 748 Retinoids and the treatment of non-small cell lung cancer: The Memorial Sloan-Kettering experience in 92 patients (1997) (0)
- Abstract P4-06-07:PIK3CA-mutant breast phyllodes tumors show a uniformly aggressive histology and significant mutual exclusivity withMED12mutation (2020) (0)
- Detection of targetable kinase fusions in 7260 patients in an integrated cancer system. (2018) (0)
- Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to bladder cancer. (2017) (0)
- 2813 Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma (2015) (0)
- for Acquired Endocrine Resistance in Breast Cancer : A Novel Mechanism α D 538 G Mutation in Estrogen Receptor-Updated (2013) (0)
- Abstract P2-05-03: Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Safety profile, activity and associations of molecular alterations in the PI3K/AKT/mTOR pathway (2015) (0)
- Abstract 4667: The complex genomic landscape of glial tumors reveals distinct subclasses and potential therapeutic targets associated with clinical responses to targeted inhibitors (2015) (0)
- Abstract PD8-01:CDH1mutated classic and pleomorphic invasive lobular breast carcinomas differ in genomic signatures and opportunities for targeted and immunotherapies (2018) (0)
- Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape (2019) (0)
- GE-04COMPREHENSIVE GENOMIC PROFILING (CGP) OF PEDIATRIC GLIOMAS REVEALS A HIGH FREQUENCY OF CLINICALLY RELEVANT GENOMIC ALTERATIONS (CRGA) ASSOCIATED WITH BENEFIT FROM TARGETED THERAPY (2015) (0)
- Abstract 3576: Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC) (2015) (0)
- 579 A prospective study of the prevalence of neurologic disease and autoantibodies in small cell lung cancer (SCLC) (1997) (0)
- 415 Comprehensive next generation sequencing of solid tumors from 669 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations (2014) (0)
- Analysis of EGFR mutant upper tract and bladder urothelial carcinoma (UC) reveals distinct mutational landscape. (2019) (0)
- Utility of Combined DNA and RNA Next Generation Sequencing in Leukemias for Identification of Prognostic and Therapeutically Relevant Genomic Alterations in Clinical Practice (2014) (0)
- L2.2 Utilizing Next Generation Sequencing (NGS) in Clinical Oncology (2012) (0)
- MP49-12 PENILE AND UTERINE CERVICAL SQUAMOUS CELL CARCINOMAS: A COMPARATIVE GENOMIC PROFILING STUDY (2019) (0)
- Abstract 1772:PIK3CAC2 domain deletions hyperactivate PI3K, generate oncogene dependence and are exquisitely sensitive to PI3Kα inhibitors (2017) (0)
- Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with pancreatic ductal adenocarcinoma (PDA). (2017) (0)
- Abstract 2367: Identification of ALK alternative transcription initiation in BRAF-negative metastatic melanoma patients (2017) (0)
- Abstract 4927: Next-generation sequencing enables new approach to molecular cytogenetics (2015) (0)
- PD60-01 CASTRATE RESISTANT TMPRSS2: ERG FUSION POSITIVE AND TMPRSS2: ERG WILD TYPE REFRACTORY ACINAR AND NEUROENDOCRINE PROSTATE CANCER DIFFER IN GENOMIC SIGNATURES AND OPPORTUNITIES FOR TARGETED AND IMMUNOTHERAPIES (2018) (0)
- Oncogene Inactivation Survival and Death Signals Can Predict Tumor Response to Therapy After (2011) (0)
- Comprehensive genomic profiling in malignant myoepithelioma to suggest potential alternative diagnosis. (2020) (0)
- Abstract 3105: Serial profiling of ctDNA identifies clinically actionable genomic evolution in high-risk neuroblastoma (2019) (0)
- Contents Vol. 91, 2016 (2016) (0)
- Pan-squamous genomic profiling stratified by anatomic tumor site and viral association. (2018) (0)
- Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies. (2018) (0)
- Abstract 1602: Development and validation of an NGS-based assay to detect all classes of genomic alterations in circulating tumor cells (CTCs) from patients with solid tumors (2015) (0)
- GE-07THE GENOMIC LANDSCAPE OF DIVERSE BRAIN TUMORS REVEALS KNOWN AND NOVEL ONCOGENIC ALTERATIONS FREQUENTLY ASSOCIATED WITH SENSITIVITY TO TARGETED INHIBITORS. (2014) (0)
- P-285 Tissue microarray (TMA) of mediastinoscopy specimens to assess the p53 pathway in stage IIIA non-small cell lung cancer: Impact on outcome in patients treated with pre-operative chemotherapy (2003) (0)
- for bronchioloalveolar carcinoma Clinical pattern and pathologic stage but not histologic features predict outcome (2013) (0)
- Abstract P4-15-03: Activating mutations in ERBB2/HER2 as found by FoundationOneTM represent potential therapeutic targets in breast cancer (2015) (0)
- Comprehensive genomic profiling of urothelial carcinoma of the kidney and ureter: Comparison with urothelial carcinoma of the bladder and impact on potential for targeted therapy selection. (2016) (0)
- MP71-13 GENOMIC CHARACTERIZATION OF RENAL CELL CARCINOMA WITH SARCOMATOID DEDIFFERENTIATION (2016) (0)
- Commentary on Abstracts #986 and #1015 (2000) (0)
- 115 Tirapazamine plus cisplatin in patients (pts) with advanced non-small cell lung cancer (NSCLC)☆ (1997) (0)
- Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer (2012) (0)
- Correction: PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors (2019) (0)
- Abstract P6-14-02: Genomic profiling by FoundationOne® analysis of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations (GA) (2015) (0)
- Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature. (2019) (0)
- KRAS amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA). (2019) (0)
- 818 Elevations of serum type III procollagen N-terminal propeptide during induction therapy predict lung toxicity in patients with lung cancer (1997) (0)
- Abstract 930: On-target resistance to mutant selective EGFR inhibitors develops in an allele-specific manner dependent on the original EGFR activating mutation (2019) (0)
- Clinical and genomic alterations features of patients with advanced colitis associated cancers (CAC). (2017) (0)
- Erratum: Ifosamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy (American Journal of Clinical Oncology: Cancer Clinical Trials (1996) (0)
- FGFR2: A pan-genomic target. (2019) (0)
- Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL (2015) (0)
- Utility of comprehensive genomic profiling (CGP) to distinguish neoplasms pathologically diagnosed as PanNETs and PanNECs and identify potentially actionable genomic alterations (GA). (2018) (0)
- Comprehensive genomic profiling of advanced colorectal carcinoma in the course of clinical care to identify KRAS insertions not detected by focused molecular testing. (2016) (0)
- Comprehensive genomic profiling (CGP) of mixed hepatocellular cholangiocarcinomas (cHCC-CCA) (2019) (0)
- PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response. (2014) (0)
- Genomic landscape of urothelial cancer (UC), chemotherapy (CTX) response, and outcome based on smoking status. (2016) (0)
- Abstract 4757: A clinically validated comprehensive companion diagnostic platform for care of patients with advanced cancer (2018) (0)
- PATH-38. COMPREHENSIVE GENOMIC PROFILING OF OLIGODENDROGLIOMAS REFINES TUMOR DIAGNOSES AND IDENTIFIES PATIENTS FOR TARGETED THERAPIES AND IMMUNE CHECKPOINT INHIBITORS (2017) (0)
- Comparison of CISH and FISH for detection of EGFR copy number in lung adenocarcinoma and correlation with EGFR and KRAS mutation status and EGFR immunoreactivity (2008) (0)
- Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay (2018) (0)
- DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site. (2016) (0)
- Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent SND1-BRAF fusion. (2014) (0)
- Comprehensive Mutational Profiling In Myelodysplastic Syndromes Treated With Decitabine and Tretinoin (2013) (0)
- Comprehensive genomic profiling of acral and mucosal melanomas to support clinical decision making. (2018) (0)
- Comprehensive genomic profiling identifies clinically relevant genomic alterations in relapsed and metastatic penile squamous cell carcinoma. (2015) (0)
- Comprehensive genomic profiling in colorectal cancer (CRC) to identify differing frequencies of clinically relevant genomic alterations (CRGA) in tumors of patients (pts) less than age 50 as compared to those of pts over age 65. (2016) (0)
- Clinical Utility of Comprehensive Profiling of Genomic Alterations in Hematologic Malignancies (2014) (0)
- 10-Propargyl-10-deazaaminopterin (2003) (0)
- Utilization and clinical impact of genomic profiling for EGFR and ALK in non-squamous non-small cell lung cancer (NSCLC) in the community setting. (2015) (0)
- KRAS amplification and mutation are independent events in gastroesophageal adenocarcinomas (GEA). (2019) (0)
- Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms (2015) (0)
- Comprehensive genomic profiling of primary intracranial malignant neoplasms to reveal frequency of clinically relevant genomic alterations. (2015) (0)
- Genomic Alterations of Histone Modification Genes Are Significantly Less Common in Non-Hodgkin Lymphomas of Adolescents and Young Adults Compared to Older Patients (2014) (0)
- Comprehensive Genomic Profiling (CGP) Informs Molecular Diagnosis, Prognosis, and Therapeutic Decision-Making for Patients with Angioimmunoblastic T-Cell Lymphoma (AITL) (2017) (0)
- Identification of Actionable Genomic Alterations Across Different Lymphoma Histologies Using a Comprehensive Next Generation Genomic Sequencing Clinical Assay (2014) (0)
- Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy. (2018) (0)
- Abstract 2582: A novel PI3K/Akt-pathway activation biomarker using comprehensive genomic profiling (CGP) for clinical trial assay (2018) (0)
- Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression (2014) (0)
- Correlation of genomic alterations with outcome in patients (pts) with urothelial carcinoma (UC). (2016) (0)
- HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Vincent A. Miller?
Vincent A. Miller is affiliated with the following schools:
